The Association between Immune-Histochemical Expressions of Program death ligand with Some Aggressive Features of Prostate Cancer
DOI:
https://doi.org/10.22401/g18c0m59Keywords:
Immunoglobin, H&E , IHC , PC , PDL-1Abstract
Prostate cancer (PC), accounts for more than one-fourth of all cancer diagnoses, and the most frequently diagnosed cancer among men in 2022. The immunoglobulin (IG) Program death ligand-1(PD-1) cell surface receptor is predominantly expressed on the surface of many cells. The purpose of this study was to demonstrate the relationship between Program death ligand expression and some aggressive features of prostate cancer including perineural invasion, vascular invasion and necrosis. Thirty cases of prostate cancer with age range from 60 to 80 year old and 30 cases of normal prostate tissue with age under 25 year old were separated into two groups in a retrospective case-control research that encompassed 60 cases. All malignant cases were examined by consultant pathologists for the diagnosis of prostate carcinoma, and each block of tissue was divided into two slides, one for hematoxylin and eosin (H&E) staining and the other for immunoglobulin (IHC) staining of PDL-1. The expression pattern of Program Death Ligand was investigated in these samples and its relationship to particular clinic-pathological characteristics. Despite it was not expressed in healthy prostatic tissue, program death ligand demonstrated to be positive in prostate cancer with vascular invasion, perineural invasion, and necrosis, while it was negative in healthy prostatic tissue. High expression of Program death ligand was correlated with poor differentiation, neural invasion, and vascular invasion; these criteria indicate that the expression of Program death ligand is associated with high grade and aggressive tumors. The current study confirms that perineural invasion, vascular invasion, and necrosis are all accompanied by a rise in Program death ligand expression regardless their grade and stage.
References
Siegel, L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. “Cancer statistics”. CA Cancer J. Clin., 72: 7–33, 2022.
Sejda, A.; Sigorski, D.; Gulczyński, J.; Wesołowski, W.; Kitlińska, J.; Iżycka-Świeszewska, E.; “Complexity of Neural Component of Tumor Microenvironment in Prostate Cancer”. Pathobio. J. Immuno. Mol. Cell. Biol., 87: 87–99, 2020.
Da-Rosa P.D.; De-Carbelho, V.M.; Sementili, A.; De-Matos, L.L.; Devitis, R.A. “Prognostic significance of perineural invasion in laryngeal cancer”. Arch. Head Neck Surg., 47(3): 1-6, 2019.
Wang, W.; Le, L.; Chen, N.; et al. “Nerves in the tumor microenvironment: origin and effect. Cell Dev. Biol., 8: 1-16, 2020.
AlQa’qa,’ S.; Downes, M.R.; Van-Der, T.; “Morphologic Pattern, Frequency, and Spatial Distribution of Lymphovascular Invasion Foci in Radical Prostatectomy Specimens”. Int. J. of Sur. Path. 31(6): 939-948, 2023.
Kang, M.; Lee, H.; et al.; “Genomic Features and Clinical Implications of Intraductal Carcinoma of the Prostate”. Int. J. Mol. Sci., 22(23): 34-39, 2021.
Mohammed, T.K.; Ahmed, B.S.; “The Immunohistochemical Expression of PDL-1 in Prostate Carcinoma and Benign Prostatic Hyperplasia/Clinico-Pathological Study”. Iraqi Post. Med. J., 22 (1): 16-20, 2023.
Lyford-Pike, S.; Peng, S.; Young, G.D.; Taube, J.M.; Westra, W.H.; Akpeng, B.; et al. “Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma”. Cancer Res. 73:1733-41, 2013.
Liu, Y.; Gao, Y.; Hao, H.; Hou, T. “CD279 mediates the homeostasis and survival of regulatory T cells by enhancing T cell and macrophage interactions”. FEBS Open Biol., 10: 1162–1170, 2020.
Beenen, A.C.; Sauerer, T.; Schaft, N.; Dörrie, J.; “Beyond cancer: Regulation and function of PD-L1 in health and immune-related diseases”. Int. J. Mol. Sci., 23(15): 8599-8612, 2022.
Borghaei, H.; Gettinger, S.; Vokes, E.E. et al.; “Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: Nivolumab versus Docetaxel in previously treated non–small-cell lung cancer”. J. Clin. Oncol. 39: 723-733, 2021.
Herbst, R.S.; Baas, P.; Kim, D.W. et al.; “Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (keynote-010): a randomized controlled trial”. Lancet., 387:1540–1550, 2016.
Anguilar, E.J.; Rucciuti, B.; Gainor, J.F. et al.; “Outcome to first line prembrolizumab in patients with non-small cell lung cancer and very high Pdl-1 expression”. Annals of Oncol. J., 30(10): 1-7, 2020.
Bakhaya, K.B.; Hassel, J.C.; “Biomarker for clinical benefit of immune checkpoint inhibitor treatment melanoma - A review of perspective and beyond”. Immunology 9: 1474-1485, 2018.
Hu, Y.; Chin, W.; Yan, Z. et al.; “Prognostic value of PD-L1 expression in patients with pancreatic cancer”. Medicine Baltimore J., 98(3): 1-8, 2019.
Toyokawa, G.; Takada, K.; Haratake, N. et al.; “Favorable disease free survival association with PD-L1 expression in patients with surgically resected small cell lung cancer”. Anticancer Res. 36(8): 4329-4336, 2016.
Wu, Q.; You, L.; Nepovimova, E. et al.; “Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape”. J. Hemat. Oncol. 77: 4-18, 2022.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Tamarah Kadhim Mohammed, Basim Shihab Ahmed
This work is licensed under a Creative Commons Attribution 4.0 International License.
.jpg)
